To date, there is insufficient scientific evidence to recommend a fourth dose of coronavirus vaccine to the general population according to the European Medicines Agency.
Specifically, the Dr. Marco Cavaleri, the head of the European Medicines Agency’s vaccination strategy, during today’s press conference on the course of the coronary heart disease, referred to data from Israel, the only country in the world that has approved a fourth dose for health workers and their immunocompromised patients over 60 years of age.
During the press conference, it was pointed out that in any case the risk, if the vaccines are not distributed and administered evenly throughout the world, will always be real.
In the January press release, the European Medicines Agency had stressed the need for a “long-term strategy on the types of vaccines needed to manage coronavirus”.
More specifically, according to his study data Weizmann Institute of Science, when the fourth dose is given at least 4 months after the previous one, is able to reduce the risk of serious illness more than four times compared to the three doses.
In contrast, another preliminary survey of health workers in Tel HaShomer’s Sheba Medical Center showed that the fourth dose was less effective against Omicron and did not prevent infection.
In a January press release, the European Medicines Agency stressed the need for a “long-term strategy on the types of vaccines needed to manage coronavirus”. “Repeated booster doses at very short intervals can reduce the level of antibodies that are activated by the vaccine,” said EMA chief physician Marco Cavaleri.
See all the news
Follow Skai.gr on Google News
and be the first to know all the news
Skai
